Omnicell, Inc.
Rank #268ValueOMCL · Nasdaq · Healthcare
Omnicell, Inc. (OMCL) — Rank #268 by gross profitability (GP/assets 0.25) · ROE 0.2% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0000926326 · all metrics point-in-time as of the filing date.
About
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Show moreShow less
It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc.
was incorporated in 1992 and is headquartered in Fort Worth, Texas.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- omnicell.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-28 | 2022-12-31filed 2023-03-01 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 78.8 | 82.2 | 87.3 | 86.9 |
| Stock-based compensation | 44.5 | 39.3 | 55.3 | 68.2 |
| Change in receivables | — | — | — | 60.4 |
| Change in inventory | 11.2 | (15.6) | (38.0) | 30.1 |
| Change in payables | (9.3) | 7.2 | (17.5) | (7.8) |
| Operating cash flow | 127.3 | 187.7 | 181.1 | 77.8 |
| Investing | ||||
| Capital expenditures | 40.4 | 36.5 | 41.5 | 47.5 |
| Acquisitions, net of cash | — | 0.0 | 0.0 | 3.4 |
| Investing cash flow | (60.4) | (52.8) | (55.0) | (58.7) |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | — | — | 0.0 |
| Share repurchases | 77.6 | 0.0 | 0.0 | 52.2 |
| Financing cash flow | (218.3) | (235.6) | 23.4 | (21.0) |
| Summary | ||||
| Free cash flow | 86.9 | 151.3 | 139.6 | 30.2 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?